The second is identification of mechanistically sensitive tumors, which depend heavily on CDK9-dependent transcription of selected driver genes such as MCL1, MYC, MYCN, or which are reliant on dysregulated activation of CDK2/cyclin E. A good precedent for such patient selection is the identification of a specific breast cancer subset for CDK4/6 inhibitors [28]. The gene discussed is CDK2; the disease is breast cancer.